218 related articles for article (PubMed ID: 24656094)
21. Serum AKR1B10 predicts the risk of hepatocellular carcinoma - A retrospective single-center study.
Zhu R; Xiao J; Luo D; Dong M; Sun T; Jin J
Gastroenterol Hepatol; 2019 Dec; 42(10):614-621. PubMed ID: 31495535
[TBL] [Abstract][Full Text] [Related]
22. AKR1B10 expression by immunohistochemistry in surgical resections and fine needle aspiration cytology material in patients with cystic pancreatic lesions; potential for improved nonoperative diagnosis.
Connor JP; Esbona K; Matkowskyj KA
Hum Pathol; 2017 Dec; 70():77-83. PubMed ID: 29079172
[TBL] [Abstract][Full Text] [Related]
23. IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma.
Cheng BY; Lau EY; Leung HW; Leung CO; Ho NP; Gurung S; Cheng LK; Lin CH; Lo RC; Ma S; Ng IO; Lee TK
Cancer Res; 2018 May; 78(9):2332-2342. PubMed ID: 29483095
[TBL] [Abstract][Full Text] [Related]
24. A triple stain of reticulin, glypican-3, and glutamine synthetase: a useful aid in the diagnosis of liver lesions.
Swanson BJ; Yearsley MM; Marsh W; Frankel WL
Arch Pathol Lab Med; 2015 Apr; 139(4):537-42. PubMed ID: 25822763
[TBL] [Abstract][Full Text] [Related]
25. High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma.
Wang YY; Qi LN; Zhong JH; Qin HG; Ye JZ; Lu SD; Ma L; Xiang BD; Li LQ; You XM
Sci Rep; 2017 Feb; 7():42199. PubMed ID: 28181486
[TBL] [Abstract][Full Text] [Related]
26. Compensatory upregulation of aldo-keto reductase 1B10 to protect hepatocytes against oxidative stress during hepatocarcinogenesis.
Liu Y; Zhang J; Liu H; Guan G; Zhang T; Wang L; Qi X; Zheng H; Chen CC; Liu J; Cao D; Lu F; Chen X
Am J Cancer Res; 2019; 9(12):2730-2748. PubMed ID: 31911858
[TBL] [Abstract][Full Text] [Related]
27. [Aldo-keto reductase family 1 B10 participates in the regulation of hepatoma cell cycle through p27/p-Rb signaling pathway].
Geng N; Jin YY; Zhu SX; Li YR; Zheng LY; Zhu WJ; Li YW; Han C; Dou XG; Bai H
Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):861-867. PubMed ID: 33105932
[No Abstract] [Full Text] [Related]
28. E2F1-mediated AUF1 upregulation promotes HCC development and enhances drug resistance via stabilization of AKR1B10.
Zhang T; Guan G; Zhang J; Zheng H; Li D; Wang W; Lu F; Chen X
Cancer Sci; 2022 Apr; 113(4):1154-1167. PubMed ID: 35178834
[TBL] [Abstract][Full Text] [Related]
29. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders.
Zhu ZW; Friess H; Wang L; Abou-Shady M; Zimmermann A; Lander AD; Korc M; Kleeff J; Büchler MW
Gut; 2001 Apr; 48(4):558-64. PubMed ID: 11247902
[TBL] [Abstract][Full Text] [Related]
30. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
Nassar A; Cohen C; Siddiqui MT
Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
[TBL] [Abstract][Full Text] [Related]
31. Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
Kanno M; Kawaguchi K; Honda M; Horii R; Takatori H; Shimakami T; Kitamura K; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
J Gastroenterol; 2019 Jun; 54(6):549-557. PubMed ID: 30707282
[TBL] [Abstract][Full Text] [Related]
32. Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).
Li H; Yang AL; Chung YT; Zhang W; Liao J; Yang GY
Carcinogenesis; 2013 Sep; 34(9):2090-8. PubMed ID: 23689354
[TBL] [Abstract][Full Text] [Related]
33. Genome-wide and differential proteomic analysis of hepatitis B virus and aflatoxin B1 related hepatocellular carcinoma in Guangxi, China.
Qi LN; Li LQ; Chen YY; Chen ZH; Bai T; Xiang BD; Qin X; Xiao KY; Peng MH; Liu ZM; Liu TW; Qin X; Li S; Han ZG; Mo ZN; Santella RM; Winkler CA; O'Brien SJ; Peng T
PLoS One; 2013; 8(12):e83465. PubMed ID: 24391771
[TBL] [Abstract][Full Text] [Related]
34. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls.
Wang C; Yan R; Luo D; Watabe K; Liao DF; Cao D
J Biol Chem; 2009 Sep; 284(39):26742-8. PubMed ID: 19643728
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemistry in the Diagnosis of Hepatocellular Carcinoma.
Choi WT; Kakar S
Gastroenterol Clin North Am; 2017 Jun; 46(2):311-325. PubMed ID: 28506367
[TBL] [Abstract][Full Text] [Related]
36. Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours.
Heringlake S; Hofdmann M; Fiebeler A; Manns MP; Schmiegel W; Tannapfel A
J Hepatol; 2010 Feb; 52(2):220-7. PubMed ID: 20036025
[TBL] [Abstract][Full Text] [Related]
37. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].
Tátrai P
Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466
[TBL] [Abstract][Full Text] [Related]
38. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Yan R; Zu X; Ma J; Liu Z; Adeyanju M; Cao D
Int J Cancer; 2007 Nov; 121(10):2301-6. PubMed ID: 17597105
[TBL] [Abstract][Full Text] [Related]
39. [A rare form of benign tumor of the liver possibly related to the use of oral contraceptives: focal pediculated nodular hyperplasia].
Brouquet J; Chameaud J; Vire O; Fabre P; Catanzano G; Baudet JH
Rev Fr Gynecol Obstet; 1985; 80(8-9):621-7. PubMed ID: 2997901
[TBL] [Abstract][Full Text] [Related]
40. Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocytochemical study.
Ligato S; Mandich D; Cartun RW
Mod Pathol; 2008 May; 21(5):626-31. PubMed ID: 18264086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
